Form D · Biotechnology

CytoSite BioPharma Inc.

Sudbury, MA · CIK 0001725090

Offering snapshot reported Oct 5, 2020 · SEC filing

Reported sold
$3.05M
Offering amount: $5.1M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 10, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.52M$3.05MSep 24, 2019: $2,549,995.00Sep 24, 2019Oct 5, 2020: $3,049,985.00Oct 5, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$2,549,995 → $3,049,985

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 5, 2020Amendment$3,049,985$499,990vs Sep 24, 201912SEC filing
Sep 24, 2019Initial$2,549,995No comparison12SEC filing
Aug 16, 2018Initial$4,424,985No comparison13SEC filing
May 9, 2018Initial$125,000No comparison1SEC filing
Dec 18, 2017Initial$10,760No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-349481

Source: Form D, filed Oct 5, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michel Chu Director
Ellen Cordo Executive
Robert Gailus Director
James Jenson Director, Executive
Mark Mintun Director
Stephen Sands Director
Richard Smith Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
14 Petersen Circle
Sudbury, MA, 01776